A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

Abstract:

:The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line homozygous for V617F (HEL) was treated with inhibitors of JAK2 tyrosine kinase activity and the HSP90 inhibitor 17-AAG. 17-AAG reduced HSP90 levels, but increased HSP70 levels. Phospho-STAT5, total STAT5, and total AKT levels were also reduced by 17-AAG treatment. Further, phospho-JAK2, total JAK2, and cell viability were reduced to a greater extent by 17-AAG than by the pan-JAK kinase family inhibitor JKII or the JAK2-specific inhibitor AG490, and these inhibitors failed to synergize with 17-AAG. Flow-cytometry-based assays for JAK/STAT signaling pathway and HSPs are likely to have broad clinical utility for monitoring patients with abnormalities in the JAK2 pathway.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

doi

10.1080/10428190701607576

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

2189-95

issue

11

eissn

1042-8194

issn

1029-2403

pii

782920490

journal_volume

48

pub_type

杂志文章
  • Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.

    abstract::Several clinical and cell biological features, such as sex, age, leukemic cell burden, morphologic FAB type, and immunophenotype, have prognostic value in childhood acute lymphoblastic leukemia (ALL). The explanation for their prognostic significance is unclear, but might be related to cellular drug resistance. We pro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509112198

    authors: Kaspers GJ,Pieters R,Van Zantwijk CH,Van Wering ER,Veerman AJ

    更新日期:1995-11-01 00:00:00

  • Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.

    abstract::Aim of this multicenter-study was to evaluate rate and duration of remissions and to examine toxicity of cladribine in low-grade lymphomas as first-line therapy or in first relapse using intermittent 2-hour-infusion of cladribine. A total of 294 courses, median of 5 courses per patient, were administered to 66 evaluab...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428199909145712

    authors: Rummel MJ,Chow KU,Jäger E,Leimer L,Hossfeld DK,Bergmann L,Peters HD,Hansmann ML,Meyer A,Hoelzer D,Mitrou PS

    更新日期:1999-09-01 00:00:00

  • The insulin-like growth factor system in hematopoietic cells.

    abstract::The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290011958

    authors: Zumkeller W

    更新日期:2002-03-01 00:00:00

  • Complex IgA gammopathy in Gaucher's disease.

    abstract::A 55-year-old Jewish patient was simultaneously diagnosed as having Gaucher's disease and IgA multiple myeloma. Serum protein electrophoresis and immunoelectrophoresis showed two different IgA kappa type monoclonal spikes. After four years of observation, a rapid fatal course of disease developed together with express...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509054770

    authors: Shvidel L,Hurwitz N,Shtalrid M,Zur S,Oliver O,Berrebi A

    更新日期:1995-12-01 00:00:00

  • The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.

    abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600757894

    authors: Micallef IN,Remstein ED,Ansell SM,Colgan JP,Inwards DJ,Johnston PB,Lewis JT,Markovic SN,Porrata LF,White WL,Witzig TE,Ristow K,Habermann TM

    更新日期:2006-09-01 00:00:00

  • Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias.

    abstract::A family with erythroleukemia is presented, in which father and son were diagnosed at the same age, but 20 years apart, with almost identical clinical and morphological features of the disease. No environmental factors were identified. The karyotypic abnormalities of the bone marrow blasts in the son demonstrated 2 ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057551

    authors: Novik Y,Marino P,Makower DF,Wiernik PH

    更新日期:1998-07-01 00:00:00

  • Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.

    abstract::Bone marrow toxicity is a great challenge for physicians treating patients with non-Hodgkin's lymphoma (NHL) and prescribed chemotherapy. Granulocyte colony-stimulating factor (G-CSF) prevents myelotoxicity, but the optimal timing and scheduling of G-CSF administration has not been ascertained. We investigated leukocy...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199509054760

    authors: Sawada KI,Sato N,Kohno M,Hannda H,Yasukouchi T,Tanngo M,Hirayama A,Koike T

    更新日期:1995-12-01 00:00:00

  • Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

    abstract::Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864352

    authors: Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

    更新日期:2021-01-11 00:00:00

  • Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein.

    abstract::Serum amino-terminal pro-brain natriuretic peptide (NT-proBNP) is considered as a prognostic marker in patients with severe sepsis or septic shock, but no data are available on NT-proBNP kinetics in hematological patients with neutropenic fever. Altogether 70 hematological patients with neutropenic fever were included...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428191003743478

    authors: Hämäläinen S,Juutilainen A,Kuittinen T,Nousiainen T,Matinlauri I,Pulkki K,Koivula I,Jantunen E

    更新日期:2010-06-01 00:00:00

  • DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

    abstract::This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1397659

    authors: Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

    更新日期:2018-08-01 00:00:00

  • The role of interleukin-3 in classical Hodgkin's disease.

    abstract::Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400013712

    authors: Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

    更新日期:2005-03-01 00:00:00

  • Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

    abstract::Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509054750

    authors: Vacca A,Ribatti D,Roncali L,Dammacco F

    更新日期:1995-12-01 00:00:00

  • Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

    abstract::The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.778408

    authors: Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

    更新日期:2013-11-01 00:00:00

  • Surrogate end points for long-term outcomes in chronic myeloid leukemia.

    abstract::The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.772607

    authors: Akwaa F,Liesveld J

    更新日期:2013-10-01 00:00:00

  • Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.

    abstract::Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1157873

    authors: Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

    更新日期:2016-11-01 00:00:00

  • Allergic reactions associated with pegaspargase in adults.

    abstract::One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic reactions based on the Common Terminology Criteria for Adverse Events (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1105369

    authors: Chang A,Kim M,Seyer M,Patel S

    更新日期:2016-07-01 00:00:00

  • Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.

    abstract::Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1028053

    authors: Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

    更新日期:2015-01-01 00:00:00

  • Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

    abstract::Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictor...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190600822128

    authors: Keats JJ,Reiman T,Belch AR,Pilarski LM

    更新日期:2006-11-01 00:00:00

  • DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

    abstract::We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199809059229

    authors: Reiser M,Schnell R,Straub G,Borchmann P,Wilhelm M,Ubelacker R,Wörmann B,Münch R,Diehl V,Engert A

    更新日期:1998-10-01 00:00:00

  • Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

    abstract::Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1265113

    authors: Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

    更新日期:2017-08-01 00:00:00

  • Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.

    abstract::Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1605070

    authors: Modi D,Kim S,Singh V,Ayash L,Alavi A,Ratanatharathorn V,Uberti JP,Deol A

    更新日期:2019-11-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

    abstract::Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been propose...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1630618

    authors: Clifford M,Bannon S,Bednar EM,Czerwinski J,Davis J,Dunnington L,Shahrukh Hashmi S,DiNardo CD

    更新日期:2019-12-01 00:00:00

  • Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

    abstract::The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with vi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.769219

    authors: Honeychurch J,Melis MH,Dovedi SJ,Mu L,Illidge TM

    更新日期:2013-09-01 00:00:00

  • Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.

    abstract::Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009060321

    authors: Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

    更新日期:2000-06-01 00:00:00

  • Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution.

    abstract::Interleukin-7 (IL-7) is a critical cytokine in early B and T cell development. Peripheral T cell expansion and thymopoiesis and is a result of the ongoing reconstitution from uncommitted stem cells after transplant. We investigated the efficacy of ex vivo incubated bone marrow cells treated with recombinant human IL-7...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1016935

    authors: Abdul-Hai A,Ben Yehuda A,Slavin S,Or R

    更新日期:2015-01-01 00:00:00

  • Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.

    abstract::Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited. We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like reg...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500178688

    authors: Zinzani PL,Tani M,Alinari L,Molinari AL,Stefoni V,Visani G,Gentilini P,Guardigni L,Fina M,Baccarani M

    更新日期:2005-10-01 00:00:00

  • Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

    abstract::After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.685733

    authors: Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

    更新日期:2012-11-01 00:00:00

  • Expression of c-kit receptor (CD117) and CD34 in leukemic cells.

    abstract::The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509049769

    authors: Muroi K,Nakamura M,Amemiya Y,Suda T,Miura Y

    更新日期:1995-01-01 00:00:00

  • The presence of circulating clonal CD19+ cells in multiple myeloma.

    abstract::Multiple myeloma (MM) is a B-cell malignancy characterized by the expansion of mature plasma cells (PC) localized in the bone marrow (BM). Several studies have identified circulating clonotypic CD19+ cells at a differentiation stage preceding the PC. The level of circulating clonotypic CD19+ cells is highly variable b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097764

    authors: Rasmussen T

    更新日期:2001-11-01 00:00:00